Pembrolizumab
Generic name: pembrolizumab [ PEM-broe-LIZ-ue-mab ]
Brand name: Keytruda
Dosage form: intravenous solution (25 mg/mL)
Drug class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
What is pembrolizumab?
Pembrolizumab (Keytruda) is a type of immunotherapy used to treat cancers, including lung cancer, breast cancer, melanoma, head and neck cancer, and many more. Pembrolizumab works by helping your immune system to slow or stop the growth and spread of cancer cells in the body.
Pembrolizumab is an anti-PD-1 therapy that works (mechanism of action) by blocking the PD-1 (programmed death receptor-1) receptor, which helps it stop cancer cells from hiding from the immune system, resulting in decreased tumor growth.
Pembrolizumab is used alone or in combination with other medicines to treat certain types of cancer, such as:
- skin cancer (melanoma, Merkel cell carcinoma, squamous cell carcinoma);
- lung cancer;
- head and neck cancer;
- classical Hodgkin lymphoma;
- primary mediastinal large B-cell lymphoma;
- cancer of the kidney, bladder, and urinary tract;
- colorectal cancer;
- liver cancer;
- triple-negative breast cancer;
- cancer of the cervix or uterus;
- advanced stomach or esophageal cancer;
- locally advanced unresectable or metastatic biliary tract cancer (BTC) or
- a type of cancer that laboratory testing proves to have certain specific DNA mutations.
Pembrolizumab is often given when the cancer has spread to other parts of the body, or cannot be treated with surgery or radiation, or when other cancer treatments did not work or have stopped working.
For some types of cancer, pembrolizumab is given only if your tumor tests positive for "PD-L1", or if the tumor has been tested for a specific genetic marker (including "EGFR," "ALK," "HER2/neu," or "TMB").
Your doctor will review your specific type of cancer and past treatment history and other available treatments to determine if pembrolizumab is right for you.
Warnings
Pembrolizumab can change the way your immune system works, which may cause certain side effects that can lead to serious medical problems.
Pembrolizumab can cause serious or life-threatening side effects. Some side effects may need to be treated with other medicine, and your cancer treatments may be delayed. You will need frequent medical tests to help your doctor determine if it is safe for you to keep receivingthis medicine.
Call your doctor at once if you have: skin problems, vision problems, fever, swollen glands, neck stiffness, chest pain, cough, shortness of breath, muscle or joint pain, pale skin, weakness, diarrhea, severe stomach pain, blood in your stools, bruising or bleeding, dark urine, yellowing of the skin or eyes, a hormonal disorder (frequent headaches, feeling light-headed, rapid heartbeats, a deeper voice, increased thirst or urination, feeling cold, weight gain or loss), or a change in the amount or color of your urine.
Before taking this medicine
To make sure pembrolizumab is safe for you, tell your doctor if you have ever had:
-
an autoimmune disorder such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, lupus, or psoriasis;
-
received or plan to receive a stem cell transplant that uses donor stem cells;
-
an organ transplant;
-
radiation to your chest; or
-
a nerve-muscle disorder such as myasthenia gravis or Guillain-Barré syndrome.
Pembrolizumab may harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant. Use effective birth control while using pembrolizumab and for at least 4 months after your last dose. Tell your doctor if you become pregnant.
Do not breastfeed while using pembrolizumab, and for at least 4 months after your last dose.
How is pembrolizumab given?
Pembrolizumab is given as an infusion into a vein, usually once every 3 to 6 weeks. A healthcare provider will give you this injection.
This medicine must be given slowly over 30 minutes.
You will need frequent medical tests to help your doctor determine if it is safe for you to keep receiving pembrolizumab. Do not miss any follow-up visits.
Related/similar drugs
Keytruda, Yervoy, Enhertu, Verzenio, Opdivo, methotrexate, Arimidex, pembrolizumab, hydroxyurea, megestrol
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your pembrolizumab injection.
What happens if I overdose?
In a medical setting an overdose would be treated quickly.
What should I avoid while receiving pembrolizumab?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Pembrolizumab side effects
Common pembrolizumab side effects
-
nausea, vomiting, stomach pain, loss of appetite, diarrhea, constipation, weight loss;
-
low blood sodium levels, abnormal thyroid, liver and kidney function tests;
-
low blood cell counts;
-
tingling or numbness in your hands or feet, loss of movement in the arms and legs;
-
bleeding;
-
pain and burning when you urinate;
-
fever, headache, feeling weak or tired, dizziness, trouble sleeping;
-
cough, hoarse voice, feeling short of breath;
-
changes in your sense of taste, dry skin and dry eyes;
-
itching, hair loss, rash or blisters on your hands or feet;
-
increased blood pressure;
-
pain in your muscles, bones, or joints; or
-
mouth sores or swelling around your mouth, nose, eyes, throat, intestines or vagina.
Serious pembrolizumab side effects
Get emergency medical help if you have signs of an allergic reaction to pembrolizumab (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Seek medical treatment if you have a serious drug reaction that can affect many parts of your body. Symptoms may include skin rash, fever, swollen glands, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes.
Some side effects may occur during the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.
Pembrolizumab causes your immune system to attack tumor cells, but it could also attack healthy organs and tissues in your body. This could lead to serious or life-threatening side effects on your lungs, liver, pancreas, kidneys, intestines, thyroid, or adrenal glands.
Call your doctor at once if you have:
-
new or worsening cough, chest pain, shortness of breath;
-
pale skin, easy bruising or bleeding;
-
severe muscle pain, cramps, weakness, neck stiffness;
-
double or blurry vision;
-
confusion, sleep or memory problems, changes in mood or behavior, balance problems;
-
numbness, tingling, burning pain, redness, rash, or blisters on your hands or feet;
-
fever or flu-like symptoms, swollen glands, sores in your mouth, throat, nose, or on your genital area;
-
diarrhea, severe stomach pain or tenderness, bloody or tarry stools;
-
feeling sick or uneasy, with pain or swelling near your transplanted organ;
-
high blood sugar = increased thirst, increased urination, dry mouth, fruity breath odor;
-
kidney problems = swelling, blood in your urine, urinating less, loss of appetite, feeling tired or short of breath;
-
liver problems = swelling around your midsection, right-sided upper stomach pain, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
-
hormonal problems = unusual headaches, sensitivity to light, eye problems, rapid heartbeats, increased sweating, extreme tiredness, weight gain or weight loss, increased hunger or thirst, increased urination, hair loss, feeling cold, constipation, hoarse or deepened voice, dizziness, fainting, decreased sex drive; or
-
low red blood cells (anemia) = pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet.
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect pembrolizumab?
Tell your doctor about all other cancer treatments you are receiving.
Other drugs may interact with pembrolizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Ingredients
Keytruda
Active ingredient: pembrolizumab
Inactive ingredients: L-histidine, polysorbate 80, sucrose, and water for injection
Manufacturer
Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA.
Pembrolizumab Biosimilars
Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.
Reference products
These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for pembrolizumab.
Keytruda (pembrolizumab) - Merck Sharp & Dohme LLC
Formulation type | Strength |
---|---|
Single-Dose Vial | 100 mg/4 mL (25 mg/mL) |
Single-Dose Vial | 50 mg Discontinued |
View Keytruda information in detail.
Popular FAQ
Pembrolizumab vs. nivolumab: How do they compare?
Pembrolizumab and nivolumab are both prescription medications used to treat various types of cancers, including solid tumors and blood cancers. They may be used alone or in combination with other medicines for cancers that are more advanced, have spread in the body, or are no longer responding to previous treatments. Continue reading
What type of cancer is pembrolizumab used for?
Pembrolizumab, an immunotherapy checkpoint inhibitor, was first approved in September 2014. Since that time at least 20 uses in cancer have been approved by the FDA, ranging from skin cancer to lung cancer. Pembrolizumab is now approved to treat certain lymphomas, a type of blood cancer, in addition to solid tumors. Continue reading
How are Inlyta and Keytruda used in kidney cancer?
Inlyta and Keytruda are given as a combination therapy for first-line treatment of kidney cancer (advanced renal cell carcinoma) in adults. Inlyta is an oral medication given 2 times per day and Keytruda is an intravenous (IV) infusion given every 3 weeks or every 6 weeks. Continue reading
How does pembrolizumab affect the immune system?
Pembrolizumab (Keytruda) is a type of immunotherapy medicine used to treat many different types of cancer. Immunotherapy can sometimes cause your immune system to attack healthy organs and tissues and lead to side effects. These side effects may be serious or life-threatening. This may happen anytime during or after treatment. Continue reading
How is pembrolizumab (Keytruda) administered?
Pembrolizumab (brand name: Keytruda) is a cancer medicine given into your vein as a slow intravenous (IV) infusion that usually takes about 30 minutes. You will most likely receive this treatment in an outpatient clinic or hospital setting every 3 or 6 weeks. Continue reading
How does pembrolizumab kill cancer cells?
Pembrolizumab (Keytruda) is a type of immunotherapy drug called an Immune Checkpoint Inhibitor. It binds to the PD-1 receptor on the T-cell to help block cancer cells from linking to and inactivating the cancer-fighting T-cells. While having an effect on the tumor, this could also affect normal healthy cells. Continue reading
Is lenvatinib / pembrolizumab used in endometrial cancer?
Pembrolizumab (Keytruda) is approved by the FDA to be used in combination with lenvatinib (Lenvima) for the treatment of certain patients with advanced endometrial cancer that is not MMR deficient (dMMR) or MSI high (MSI-H) after at least one other drug treatment has been tried. Continue reading
More FAQ
References
More about pembrolizumab
- Check interactions
- Compare alternatives
- Reviews (259)
- Side effects
- Dosage information
- During pregnancy
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use pembrolizumab only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2024 Cerner Multum, Inc. Version: 15.01.